Moreover, recently, cenicriviroc, a dual CCR2/CCR5 antagonist, was reported to be able to significantly reduce fibrosis and the NAFLD activity score in a NASH model [143]. This evidence concerns the gene CCR2 and metabolic dysfunction-associated steatohepatitis.